Natera, Inc. (NASDAQ: NTRA) – Securities Fraud Investigation
Natera Loses False Advertising Trial; Natera Stock Drops Significantly on Short Seller Report – Securities Investigation on Behalf of Natera Shareholders.
Kehoe Law Firm, P.C. is investigating whether Natera, Inc. (“Natera or the “Company”) (NASDAQ: NTRA) violated federal securities laws.
IF YOU INVESTED IN NATERA STOCK AND SUFFERED FINANCIAL LOSSES, PLEASE CLICK HERE TO ACCESS KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE TO PROVIDE DETAILS OF YOUR NATERA STOCK HOLDINGS.
On March 15, 2022, before the market opened, CareDX, Inc. announced that it won its false advertising case against Natera.
On this news shares of Natera, Inc. stock fell 12% in premarket trading on March 15, 2022.
On March 9, 2022, Hindenburg Research published a short report addressing Natera, entitled “Natera: Pioneers In Deceptive Medical Billing.” Among other allegations, Natera stated that “[b]ased on more than 2 dozen interviews with former Natera employees, patients and industry experts, a review of hundreds of online complaints, FOIA requests to state Medicaid offices and state Attorneys General, and the company’s financial filings, we show how Natera’s revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers.”
Following publication of the Hindenburg Research report, Natera’s stock price fell $17.95 per share, or 32.79%, to close at $36.80 per share on March 9, 2022.